For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Polyethylene glycol (PEG) is a synthetic polymer composed of repeating ethylene glycol (-CH2-CH2-O-) units. It has low toxicity, is strongly hydrophilic and has a large exclusion volume in aqueous solution1. The covalent attachment of PEG (PEGylation) is commonly used to modify a variety of proteins and drugs2–4. PEGylation can offer several benefits including decreased immunogenicity, increased bioavailability, and optimized pharmacokinetics5.
Due to the uncharged and biocompatible nature of PEG, it is not very immunogenic, making PEG very difficult to raise antibodies against. After extensive development, we have successfully generated multiple high-quality PEG RabMAb primary antibodies.
An anti-PEG antibody can be used to monitor a drug's pharmacokinetics, including distribution, metabolism and excretion. Also, it can be used for the quality control of PEGylated molecules in ELISA, WB, and IHC.
View the complete range of anti-PEG products and their corresponding data here.
1. Guiotto, A. et al. (2004), Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation ,Bioorg. Med.Chem. 12, 5031–5037.
2. Wong, S.S. (1991), Reactive groups of proteins and their modifying agents. In Chemistry of Protein conjugation and cross-linking, p. 13, CRC Press.
3. Caliceti, P. et al. (1993), Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification, J. Bioact. Comp. Polym. 8,41–50.
4. Frank Leenders, celares GmbH, Berlin, Germany (2006), PEGylation technology and biopharmaceuticals. Biopharmaceuticals,39-40
5. Zhang, P. et al (2016). Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Release. 244(Pt B): 184–193.